Biotech’s boom continues

Professional investor Daniel Koller picks six stocks to profit from the continuing biotech boom.

Each week, aprofessional investor tells us where he'd put his money. This week:Daniel Koller of BB Biotech investment trust.

There are several factors fuelling the strong fundamentals of biotech. These include regulatory approvals of new biotech drugs, vigorous mergers and acqusitions (M&A) activity as bigger companies take over smaller ones, and successful clinical trials of new treatments. In the first six months of 2017, there were 23 drug approvals more than there were in the whole of 2016.

An ageing population is a major factor in powering innovation in medicine and keeping healthcare spending at a high level. Advances in medical innovation are creating benefits for patients and so the money is being found by governments and patients to pay for them. There are many opportunities for investors to do in-depth analysis to find value in product launches and clinical data updates.

At the recent American Society of Clinical Oncology conference looking at cancer treatments, several companies announced successful clinical trials, especially in the field of immuno-oncology. We think this shows the area will remain a hotbed of drug development in the years to come. In response to this trend, we have increased our oncology weighting, adding holdings in companies investigating cancer immunotherapies such as Kite Pharma (Nasdaq: KITE), Juno Therapeutics (Nasdaq: JUNO) and MacroGenics (Nasdaq: MGNX).

Further positive news comes in the fact that M&A is bouncing back. In the last few years, we have seen more consolidation. The number of companies that want to do deals is increasing, and many of the small- and mid-cap firms are on the radar for potential acquirers. Big pharmaceutical companies have over $500bn in cash to deploy to fill their relatively sparse pipelines of new drugs. In the face of this imperative, consolidation is inevitable.

A prime example of such a move was the acquisition of Actelion for $30bn by Johnson & Johnson (NYSE: JNJ), which was completed last month. This acquisition provided Johnson & Johnson with differentiated medicines and promising late-stage products.

We expect to see a steady stream of clinical results news-flow as 2017 progresses, and a growing number of product approvals compared to 2016. This will attract more investor attention to the biotech sector as a whole and it should help stocks make further gains.

We are maintaining our approach of building a portfolio of a small number of core holdings, plus some mid- and small-caps that have the potential to grow faster than the market. Growing companies that are poised to become large caps, such as US-based companies Incyte (Nasdaq: INCY) and Ionis (Nasdaq: IONS), are particularly attractive.

Recommended

Three safe bets on the growing online gambling sector
Share tips

Three safe bets on the growing online gambling sector

Professional investor Aaron Fischer, creator of the Fischer Sports Betting and iGaming ETF, picks three of his favourite online gambling stocks.
29 Nov 2021
Two outstandingly cheap UK stocks in an age of mad valuations
UK stockmarkets

Two outstandingly cheap UK stocks in an age of mad valuations

In these times of nutty company valuations, there is still plenty of opportunity around, says Merryn Somerset Webb. Take these two stocks, for example…
26 Nov 2021
Four of the best digital healthcare stocks to buy now
Share tips

Four of the best digital healthcare stocks to buy now

Thanks to Covid-19, policymakers and investors have become more aware of the wide array of opportunities in the sector. The good news is that we are a…
26 Nov 2021
Share tips of the week – 26 November
Share tips

Share tips of the week – 26 November

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
26 Nov 2021

Most Popular

Don’t worry about the global population explosion – it’s unlikely to happen
Investment strategy

Don’t worry about the global population explosion – it’s unlikely to happen

One of the many things we are taught to worry about is the fast-rising global population. But in fact, says Merryn Somerset Webb, the opposite is tru…
15 Nov 2021
Four of the best new investment trust listings
Investment trusts

Four of the best new investment trust listings

Diversify your portfolio and benefit from rising dividends with these four new investment trusts coming to the market soon.
15 Nov 2021
Is it time to remortgage your home?
Mortgages

Is it time to remortgage your home?

Banks are already starting to prepare for higher interest rates, says Alex Rankine. Should you, too?
23 Nov 2021